BrainChild Bio is a kids-first, clinical-stage biotechnology company spun out of Seattle Children's in December 2023 that develops CAR T-cell therapies for tumors of the central nervous system, prioritizing pediatric indications such as DIPG while extending its platform into adult tumors including glioblastoma. Its lead candidate BCB-276, a B7-H3-targeted autologous CAR T-cell therapy delivered directly into the cerebrospinal fluid via an indwelling reservoir-catheter, is in a pivotal Phase 2 trial for DIPG, with a second triple-targeting candidate, BCB-214, being advanced toward initial clinical testing in glioblastoma.
1
Round
1
Industry
4
Tags
Sep 8, 2026
Latest raise
Funding activity · 1 round
Sep 8, 2026
$116M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
